CTT Pharmaceutical Holdings, Inc. (OTCQB:CTTH) announced today that its CEO will issue a letter to shareholders on December 2, 2025. The letter will provide updates on several initiatives aimed at advancing the company's strategic direction.
Among the key topics, the letter will address progress on the company's S-1 filing, which would enable CTT to become a full SEC reporting company. This status would grant access to funding from its equity line of credit and help accelerate growth by monetizing the company's patents. According to the announcement, becoming a full SEC reporter is a critical step toward enhancing transparency and attracting institutional investment.
Additionally, the CEO will outline ongoing operational initiatives, including steps toward preparing for manufacturing capabilities. These efforts are part of CTT's broader commercialization strategy, which also involves updates on strategic partners aligned with the company's goals. The letter is expected to highlight how these partnerships support the path to market for CTT's therapeutic drug delivery technologies.
Shareholders will also receive an update on the recent submission of a peer-reviewed scientific manuscript. The company describes this manuscript as illuminating the scientific foundation behind what it believes is a transformative technology in therapeutic drug delivery. The research is expected to bolster the credibility of CTT's platform and support future regulatory discussions.
CTT Pharma, based in Tampa, Florida, focuses on developing innovative drug delivery systems. The upcoming shareholder letter aims to provide a comprehensive overview of the company's milestones and future direction. For more details, the original press release is available at www.newmediawire.com.
Investors and stakeholders are encouraged to review the full letter when it is issued on December 2, as it will contain detailed information on CTT's strategic initiatives and progress toward key regulatory and operational goals.
